- Home
- HOOK vs MRKR Comparison
HOOK vs MRKR Comparison
Compare HOOK & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- MRKR
- Stock Information
- Founded
- HOOK 2011
- MRKR N/A
- Country
- HOOK United States
- MRKR United States
- Employees
- HOOK N/A
- MRKR N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- HOOK Health Care
- MRKR Health Care
- Exchange
- HOOK Nasdaq
- MRKR Nasdaq
- Market Cap
- HOOK 24.5M
- MRKR 21.9M
- IPO Year
- HOOK 2019
- MRKR N/A
- Fundamental
- Price
- HOOK $1.99
- MRKR $2.16
- Analyst Decision
- HOOK Buy
- MRKR Strong Buy
- Analyst Count
- HOOK 4
- MRKR 1
- Target Price
- HOOK $10.67
- MRKR $19.00
- AVG Volume (30 Days)
- HOOK 266.1K
- MRKR 53.9K
- Earning Date
- HOOK 03-21-2025
- MRKR 11-14-2024
- Dividend Yield
- HOOK N/A
- MRKR N/A
- EPS Growth
- HOOK N/A
- MRKR N/A
- EPS
- HOOK N/A
- MRKR N/A
- Revenue
- HOOK $49,999,000.00
- MRKR $5,395,849.00
- Revenue This Year
- HOOK $148.80
- MRKR $64.48
- Revenue Next Year
- HOOK N/A
- MRKR N/A
- P/E Ratio
- HOOK N/A
- MRKR N/A
- Revenue Growth
- HOOK 143.30
- MRKR 79.04
- 52 Week Low
- HOOK $1.72
- MRKR $1.83
- 52 Week High
- HOOK $10.50
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- HOOK 45.83
- MRKR 32.84
- Support Level
- HOOK $1.80
- MRKR $1.83
- Resistance Level
- HOOK $1.99
- MRKR $2.79
- Average True Range (ATR)
- HOOK 0.24
- MRKR 0.28
- MACD
- HOOK 0.05
- MRKR -0.09
- Stochastic Oscillator
- HOOK 25.35
- MRKR 21.02
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.